(Q37707615)

22 August 2017

1 reference

title

Treatment options for advanced endometrial carcinoma (English)

1 reference

22 August 2017

Don S Dizon

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

12 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

117

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

373-381

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Extracolonic cancer in hereditary nonpolyposis colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Gynecologic Cancers in Lynch Syndrome/HNPCC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Molecular carcinogenesis of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Management of recurrent endometrioid endometrial carcinoma: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Resistance to chemotherapy and hormone therapy in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Platinum resistance: the role of DNA repair pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Molecule-targeted agents in endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.007

10.1016/J.YGYNO.2010.02.007

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference